US Patent 8629113 CTLA4-Ig immunoadhesins
Patent 8629113 was granted and assigned to Xencor on January, 2014 by the United States Patent and Trademark Office.
All edits
Edits on 10 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Dec, 2023
Golden AI
Edits made to:
Article (+154 characters)
Article
Patent abstract
The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
Edits on 25 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Gregory A. Lazar0
Matthew J. Bernett0
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08629113 CTLA4-Ig immunoadhesins US Patent 8629113 CTLA4-Ig immunoadhesins
Infobox
Patent Number
086291130
Patent Number
86291130
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
086291130
Date of Patent
January 14, 2014
0Patent Application Number
137103050
Date Filed
December 10, 2012
0Patent Primary Examiner
Edits on 21 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08629113 CTLA4-Ig immunoadhesins
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08629113
Date of patent
January 14, 2014
Patent application number
13710305
Date Filed
December 10, 2012
Patent primary examiner
Find more entities like US Patent 8629113 CTLA4-Ig immunoadhesins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.